Table 2 Clinical-pathological features of Cohort II pLGG patients
Cohort II pLGG patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Sample code | Age (years) | Gender | Site of onset | Histology | Type of resection | Progression | Progression Free Survival (months) | Overall Survival (months) | Mutational status |
ICGC_PA104 | 3 | F | Md Supra | PA | NTR | W/O | 6 | 6 | WT |
ICGC_PA144 | 2 | F | Md Supra | PA | NTR | W/O | 4 | 4 | CLCN6:BRAF Ex2:Ex11); BRAF p.E451D |
ICGC_PA14 | 5 | F | Md Supra | PA | NTR | W/O | 23 | 23 | K15B9 |
ICGC_PA159 | 5 | M | Md Supra | PA | NTR | W/O | 3 | 3 | QKI:NTRK2 (Ex6:Ex16) |
ICGC_PA4 | 1 | M | Md Supra | PA | NTR | W/O | 22 | 22 | K16B9 |
ICGC_PA54 | 4 | F | Md Supra | PA | NTR | WITH | 4 | 12 | WT |
ICGC_PA69 | 6 | F | Md Supra | PA | NTR | WITH | 17 | 17 | NF1 Large deletion (somatic); p.Q1174fs (somatic); FGFR1 p.N546K |
ICGC_PA71 | 2 | F | Md Supra | PA | NTR | WITH | 5 | 16 | NF1 p.Q959X (germline); large deletion (somatic) |
ICGC_PA84 | 9 | M | Md Supra | PA | NTR | W/O | 10 | 10 | FGFR1 p.K656E; PTPN11 p.E76A |